Against the backdrop of biotech IPOs leading the 2026 U.S. equity market with an average return of 55%, clinical-stage biopharmaceutical company Attovia Therapeutics Inc. (ATTO) has officially joined the listing wave. This early-stage drug developer, focused on immune-mediated diseases and backed by top-tier institutions including Goldman Sachs, filed its latest prospectus with the U.S. Securities and Exchange Commission on Wednesday, planning to offer 12.5 million shares at $15 to $17 per share, with maximum proceeds of approximately $212.5 million. Based on the upper end of the offering range, the biotech company’s market capitalization would approach $655 million.
Attovia initially filed its IPO application on July 14, planning to raise approximately $100 million, but strong investor demand within just two weeks prompted the company to significantly expand the offering size. At the midpoint of the range, Attovia’s fully diluted market capitalization is approximately $649 million. According to management presentations, the IPO is expected to be priced on Tuesday, August 4, with shares trading on the Nasdaq Global Market under the ticker symbol “ATTO.” Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets are serving as joint book-running managers.
As a clinical-stage biotech company, Attovia has already secured substantial financial support from top institutional investors. As of March 31, 2026, the company had raised a cumulative $255.8 million, with major shareholders including affiliates of Goldman Sachs Group, Deep Track Capital, Frazier Life Sciences, and venBio.
According to SEC filings, Deep Track Capital, Frazier Life Sciences, and venBio each hold at least 5% of the company’s shares. In April 2025, Attovia completed a $90 million Series C financing round led by Deep Track Capital, with participation from new investors including Vida Ventures, Sanofi Ventures, and Mirae Asset Capital Life Science, as well as continued support from existing investors such as Frazier Life Sciences, venBio, and Goldman Sachs Alternatives.
Attovia’s choice to go public at this time is no coincidence. Bloomberg data shows that as of July 17, the weighted average return for U.S. biotech and pharmaceutical IPOs reached 55%, while the overall IPO market excluding SPACs posted an average loss of 4.4%, meaning the biotech sector outperformed the broader market by nearly 60 percentage points.
Jack Bannister, Senior Managing Director of Equity Capital Markets at Leerink Partners, described the current environment as “the healthiest biotech IPO market in a long time,” with at least six additional biotech companies having filed IPO applications in July and expected to price before the end of summer. The strong performance of the biotech sector has been fueled by multiple factors, including a 13% year-to-date rise in the Nasdaq Biotechnology Index, a more stable regulatory environment, breakthrough clinical trial data, and a resurgence in merger and acquisition activity among large pharmaceutical companies.
